Insulet's Omnipod 5 Gets FDA Clearance for Use by Type 2 Diabetes Patients
By Paul Ziobro
Insulet said its Omnipod 5 automated insulin delivery system has been cleared by the Food and Drug Administration for people with type 2 diabetes.
The Acton, Mass.-based company said Monday the approval makes the device the first automated insulin delivery system cleared by the FDA for both type 1 and type 2 diabetes management.
"Today's announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes," Insulet Chief Executive Jim Hollingshead said.
The Omnipod is a wearable, tubeless products that provides up to three days of non-stop insulin delivery without the need to handle a needle. The Omnipod 5, meanwhile, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks and can be controlled by a compatible smartphone in the U.S. or by a controller.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
August 26, 2024 17:00 ET (21:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States